These 2 slides sum up my decision as a long termer rather than a ST trader especially this point "Revenue potential via licensing / partnering with pharma." Could happen any time.
Company Key Points
• Existing revenue of $7.4 million & growing
• CardioCel® to grow significantly in overseas markets
• Near term regenerative tissue product approval
• CardioCel® approved in Europe
• Differentiated via true tissue regeneration and preventing
calcification
• Early access approval already in Australia
• Significant revenue increase from a high unmet need
• Large potential with Prof Frazer’s DNA vaccine technology
• Multi-billion market potential
• Revenue potential via licensing / partnering with pharma
Milestones for Next 12 months
? Initial preclinical data for HPV vaccine program
? Additional “early access” approvals for CardioCel®
? Initial 510K US regulatory filing
? Initiation of the HSV immunotherapy Phase I study
? Approval for CardioCel® in Europe
• Initial revenues from CardioCel®
• Initial HSV-2 immunotherapy Phase I results
• Preclinical HPV results
• Approval for CardioCel® in USA
• Expanded regenerative tissue portfolio
These 2 slides sum up my decision as a long termer rather than a...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1135 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 88 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |